- Previous Close
41.07 - Open
42.36 - Bid 40.97 x --
- Ask 40.99 x --
- Day's Range
40.96 - 41.75 - 52 Week Range
36.24 - 52.55 - Volume
12,227,246 - Avg. Volume
8,242,861 - Market Cap (intraday)
52.631B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
15.35 - EPS (TTM)
2.67 - Earnings Date --
- Forward Dividend & Yield 2.50 (6.10%)
- Ex-Dividend Date Nov 29, 2024
- 1y Target Est
54.29
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, and other treatment areas; Chinese medicine injections; formula granules; and anti-infective drugs. It also provides related health services. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. operate as a subsidiary of China Resources Pharmaceutical Group Limited
www.999.com.cn20,318
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000999.SZ
View MorePerformance Overview: 000999.SZ
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000999.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000999.SZ
View MoreValuation Measures
Market Cap
52.63B
Enterprise Value
46.47B
Trailing P/E
15.34
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.02
Price/Book (mrq)
2.56
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
10.16
Financial Highlights
Profitability and Income Statement
Profit Margin
13.18%
Return on Assets (ttm)
6.52%
Return on Equity (ttm)
14.98%
Revenue (ttm)
25.87B
Net Income Avi to Common (ttm)
3.41B
Diluted EPS (ttm)
2.67
Balance Sheet and Cash Flow
Total Cash (mrq)
8.83B
Total Debt/Equity (mrq)
11.63%
Levered Free Cash Flow (ttm)
2.37B